Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) generates news across respiratory support, blood monitoring, and emerging diagnostics, reflecting its role as a commercial-stage medical device company. Company announcements highlight the FDA-cleared INSPIRA ART100 cardiopulmonary support system, the development of the INSPIRA ART500 oxygenation platform, and progress with the HYLA non-invasive blood sensor, including completion of a clinical study and preparation for regulatory submission.
News coverage also follows Inspira’s strategic move into liquid biopsy diagnostics. The company has outlined a non-binding term sheet and proposed transaction to acquire an advanced liquid biopsy platform focused initially on breast cancer and circulating tumor cell analysis, alongside a concurrent equity investment and a contingent value rights framework for existing shareholders. These updates provide insight into how Inspira aims to extend its expertise in blood-based technologies into oncology diagnostics.
Investors and observers can expect IINN news to include regulatory milestones, such as submissions and anticipated approvals in markets like the United Arab Emirates, as well as updates on binding purchase orders, deployment timelines, and collaborations. Recent items have covered a registered direct offering, a Standby Equity Purchase Agreement, expansion of laboratory infrastructure, and an AI-based training alliance with Bites Learning Ltd. Leadership appointments and shareholder meeting notices also appear in the company’s news flow.
This news page aggregates these developments in one place, helping readers follow Inspira’s clinical, regulatory, commercial, and corporate updates over time.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) will present its ART device at the HLTH conference in Boston from October 17-20, 2021. Co-Founder and CFO Joe Hayon will discuss the company's innovative respiratory support technology that aims to function as an 'Artificial Lung' for patients. This system is designed to enhance patient care while minimizing the need for mechanical ventilation. Inspira Technologies is part of the Israeli Medical Device & Digital Health sector and will showcase its technology at Booth 1147-15.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announced it will host a TechTalk event titled "Has COVID-19 changed the game?" on October 6, 2021, at 1:00 PM EDT. This online conference will focus on the impacts of COVID-19 on medical practices, technology innovations, and capital markets. Key speakers include Dr. Yigal Kassif discussing new COVID-19 treatment paradigms, Tal Dolev on medical startup technologies, and Miri Segal-Scharia covering capital market effects. The event aims to engage healthcare professionals and investors. For registration, visit: registration link.
Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN) has contracted GlobalLogic, a Hitachi Group Company, to enhance the digital platform of its ART device, which functions as an artificial lung. This advanced algorithm-based control platform aims to optimize patient oxygen saturation and features advanced sensor data collection. CEO Dagi Ben-Noon highlighted the significance of this project amidst the COVID-19 pandemic, aiming to improve patient care. GlobalLogic's expertise in medical technology is expected to accelerate product development and enhance healthcare experiences.
Inspira Technologies has submitted a patent application for a new supportive device aimed at improving treatment and mobility for cannulated patients, enhancing procedures for medical staff. This device is designed to assist patients requiring Extracorporeal Membrane Oxygenation (ECMO) and other treatments such as COVID-19, COPD, and ARDS. CEO Dagi Ben-Noon emphasized its potential impact on patient outcomes and rapid patent acquisition through the Israeli Patent Office, recognized for its efficiency. The ART device, functioning as an 'artificial lung,' remains untested in humans and lacks FDA approval.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced participation in two upcoming virtual conferences. Joe Hayon, Co-Founder and CFO, will be featured at the H.C. Wainwright 23rd Annual Global Investment Conference with an on-demand presentation available from September 13, 2021. He will also present at the Benzinga Small/Mid Cap Healthcare Conference on September 29, 2021, at 10:50 am ET. The company specializes in proprietary respiratory support technologies designed to stabilize patient oxygen levels without invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN) announced the successful completion of a pump bench study for its ART device, aimed at providing extracorporeal respiratory support. This milestone allows the company to advance towards the manufacturing phase of the ART device, designed to function as an "external lung" and enable patients to remain awake during treatment. The study compared Inspira's pump with leading centrifugal pumps, emphasizing its potential to minimize blood damage. However, the ART device has not yet undergone human testing or received FDA approval.
Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN) reported financial results for the six months ending June 30, 2021. The company raised $16 million through its IPO and has $4.36 million in cash. R&D expenses decreased to $1.10 million, while marketing expenses were $244,000. The net loss increased to $8.29 million compared to $4.35 million in 2020, attributed to higher finance expenses. The company aims to target a $25 billion market with its Augmented Respiration Technology (ART) and plans to double its workforce to support development efforts.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has appointed Lior Amit, CPA, to its board of directors to enhance its market strategy, particularly for the Augmented Respiration Technology (ART) system. Amit brings over 17 years of CFO experience from BBR Saatchi & Saatchi and currently serves on the boards of multiple start-ups. The ART technology aims to provide cost-effective respiratory treatment while patients are awake, potentially reducing reliance on invasive mechanical ventilation. However, the product has yet to undergo human testing or receive FDA approval.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) has appointed Dr. Dekel Stavi to its Medical Advisory Board, enhancing its strategic expansion into North America. Dr. Stavi brings extensive experience in intensive care medicine and leadership in Extracorporeal Life Support programs. His role is expected to significantly contribute to the introduction of Inspira's innovative respiratory technology, which aims to improve oxygen saturation levels in patients. However, the company's products are not yet FDA-approved and have not been tested in humans.
Aegis Capital Corp. acted as Sole Bookrunner for a $16.0 million Initial Public Offering of Common Units for Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW). The company is focused on respiratory treatments with its innovative Augmented Respiration Technology that stabilizes oxygen saturation levels, allowing patients to remain awake during treatment.
This technology aims to reduce reliance on mechanical ventilation, which is often invasive and risky.